Menkes病的治疗研究进展

毛雨鸽; 李永钦; 秦炯

doi:10.11852/zgetbjzz2019-1028

PDF(505 KB)

中国儿童保健杂志 ›› 2020, Vol. 28 ›› Issue (7) : 763-765. DOI: 10.11852/zgetbjzz2019-1028

综述

Menkes病的治疗研究进展

毛雨鸽, 李永钦, 秦炯

作者信息 +

Research progress on the treatment of Menkes disease

MAO Yu-ge, LI Yong-qin, QIN Jiong

Author information +

文章历史 +

摘要

Menkes病是一种罕见的X连锁隐性遗传病,由ATP7A基因突变引起,临床表现为神经系统症状及全身多系统功能障碍。目前治疗方法主要包括铜补充剂、抗癫痫治疗和支持治疗,随着分子遗传学技术的进步,在基因治疗方面也取得了一定进展。本文就以上治疗手段的研究进展作一综述,旨在为本病的个体化治疗提供参考。

Abstract

Menkes disease is a rare X-linked recessive genetic disease caused by ATP7A gene mutation,with varying clinical symptoms.Present treatments mainly include copper supplement,antiepileptic therapy,gene therapy and support therapy.With the development of molecular genetics technology,progress has been made on the treatment of Menkes disease.This review aims to provide reference for the individualized treatment of this disease.

导出引用

毛雨鸽, 李永钦, 秦炯. Menkes病的治疗研究进展[J]. 中国儿童保健杂志. 2020, 28(7): 763-765 https://doi.org/10.11852/zgetbjzz2019-1028

MAO Yu-ge, LI Yong-qin, QIN Jiong. Research progress on the treatment of Menkes disease[J]. Chinese Journal of Child Health Care. 2020, 28(7): 763-765 https://doi.org/10.11852/zgetbjzz2019-1028

中图分类号： R725.9

参考文献

[1] Caicedo-Herrera G,Candelo E,Pinilla J,et al.Novel ATP7A gene mutation in a patient with Menkes disease[J].Appl Clin Genet,2018,11:151-155.
[2] Patel P,Prabhu AV,Benedek TG.The history of john hans Menkes and Kinky hair syndrome[J].JAMA Dermatol,2017,153(1):54.
[3] Rangarh P,Kohli N.Neuroimaging findings in Menkes disease:a rare neurodegenerative disorder[J].Bmj Case Reports,2018,2018:bcr-2017-223858.doi:10.1136/bcr-2017-223858
[4] 李杏,袁海,陈晓兰,等.Menkes病一家系的临床与遗传学研究[J].中华实用儿科临床杂志,2018,33(24):1900-1902.
[5] Skjørringe T,Amstrup PP,Salling TS,et al.Characterization of ATP7A missense mutants suggests a correlation between intracellular trafficking and severity of Menkes disease[J].Sci Rep,2017,7:757.
[6] Prithvi A,Sharawat IK,Saini AG,et al.Epilepsy and neurodegeneration:Clues in the hair and blood vessels![J].J Pediatr,2019,206:293-293.
[7] Bonati MT,Verde F,Hladnik U,et al.A novel nonsense ATP7A pathogenic variant in a family exhibiting a variable occipital horn syndrome phenotype[J].Mol Genet Metab Rep,2017,13:14-17.
[8] Verrotti A,Cusmai R,Darra F,et al.Epilepsy in Menkes disease:an electroclinical long-term study of 28 patients[J].Epilepsy Res,2014,108(9):1597-1603.
[9] Altarelli M,Ben-Hamouda N,Schneider A,et al.Copper deficiency:causes,manifestations,and treatment[J].Nutr Clin Pract,2019.doi:10.1002/ncp.10328.
[10] Vairo FPE,Chwal BC,Perini S,et al.A systematic review and evidence-based guideline for diagnosis and treatment of Menkes disease[J].Mol Genet Metab,2019,126(1):6-13.
[11] Giampietro R,Spinelli F,Contino M,et al.The pivotal role of copper in neurodegeneration:a new strategy for the therapy of neurodegenerative disorders[J].Mol Pharm,2018,15(3):808-820.
[12] Tumer Z,Petris M,Zhu S,et al.A 37-year-old Menkes disease patient-residual ATP7A activity and early copper administration as key factors in beneficial treatment[J].Clin Genet,2017,92(5):548-553.
[13] Bhattacharjee A,Yang H,Duffy M,et al.The activity of Menkes disease protein ATP7A is essential for redox balance in mitochondria[J].J Biol Chem,2016,291(32):16644-16658.
[14] Yoganathan S,Sudhakar SV,Arunachal G,et al.Menkes disease and response to copper histidine:an Indian case series[J].Ann Indian Acad Neurol,2017,20(1):62-68.
[15] Horn N,Moller LB,Nurchi VM,et al.chelating principles in Menkes and Wilson diseases:choosing the right compounds in the right combinations at the right time[J].J Inorg Biochem,2019,190:98-112.
[16] Rakshit A,Khatua K,Shanbhag V,et al.Cu²⁺ selective chelators relieve copper-induced oxidative stress in vivo[J].Chem Sci,2018,9(41):7916-7930.
[17] Munakata M,Kodama H,Tani N,et al.Menkes disease:oral administration of glyoxal-bis(N(4)-methylthiosemicarbazonato)-copper(II) rescues the macular mouse[J].Pediatr Res,2018.doi:10.1038/s41390-018-0116-7.
[18] Hoshina T,Nozaki S,Hamazaki T,et al.Disulfiram enha nced delivery of orally administered copper into the central nervous system in Menkes disease mouse model[J].J Inherit Metab Dis,2018,41(6):1285-1291.
[19] Ogata R,Chong PF,Maeda K,et al.Long surviving classical Menkes disease treated with weekly intravenous copper therapy[J].J Trace Elem Med Biol,2019,54:172-174.
[20] Lem KE,Brinster LR,Tjurmina O,et al.Safety of intracerebroventricular copper histidine in adult rats[J].Molecular Genetics & Metabolism,2007,91(1):30-36.
[21] Fieten H,Gill Y,Martin AJ,et al.The Menkes and Wilson disease genes counteract in copper toxicosis in Labrador retrievers:a new canine model for copper-metabolism disorders[J].Dis Model Mech,2016,9(1):25-38.
[22] Lichtmannegger J,Leitzinger C,Wimmer R,et al.Methanobactin reverses acute liver failure in a rat model of Wilson disease[J].J Clin Invest,2016,126(7):2721-2735.
[23] Chong DJ,Lerman AM.Practice update:review of anticonvulsant therapy[J].Curr Neurol Neurosci Rep,2016,16(4):39.
[24] Go CY,Mackay MT,Weiss SK,et al.Evidence-based guideline update:medical treatment of infantile spasms.Report of the guideline development subcommittee of the American academy of neurology and the practice committee of the child neurology society[J].Neurology,2012,78(24):1974-1980.
[25] Ismayilova N,Leung MA,Kumar R,et al.Ketogenic diet therapy in infants less than two years of age for medically refractory epilepsy[J].Seizure,2018,57:5-7.
[26] Ojha R,Prasad AN.Menkes disease:what a multidisciplinary approach can do[J].J Multidiscip Healthc,2016,9:371-385.
[27] Salar S,Moshé SL,Galanopoulou AS.Metabolic etiologies in West syndrome[J].Epilepsia Open,2018,3(2):134-166.
[28] Kim MY,Kim JH,Cho MH,et al.Urological problems in patients with Menkes disease[J].J Korean Med Sci,2019,34(1).doi:10.3346/jkms.2019.34.e4.
[29] Lenartowicz M,Krzeptowski W,Lipiński P,et al.Mottled mice and non-mammalian models of menkes disease[J].Front Mol Neurosci,2015,8.doi 10.3389/fnmol.2015.00072.
[30] Donsante A,Yi L,Zerfas PM,et al.ATP7A gene addition to the choroid plexus results in long-term rescue of the lethal copper transport defect in a Menkes disease mouse model[J].Mol Ther,2011,19(12):2114-2123.
[31] Haddad MR,Choi EY,Zerfas PM,et al.Cerebrospinal fluid-directed rAAV9-rsATP7A plus subcutaneous copper histidinate advance survival and outcomes in a Menkes disease mouse model[J].Mol Ther Methods Clin Dev,2018,10:165-178.